Company Overview of miRagen Therapeutics, Inc.
miRagen Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of microRNA (miRNA)-targeting therapies to improve human health in disease areas of high unmet medical need. It offers miR-208, a heart-specific miRNA that protects the stressed heart from maladaptive changes and preserves cardiac function; and miR-15/195 inhibitors to reduce heart muscle cell death and promote heart muscle cell regeneration following myocardial infarction or heart attack. The company also provides miR-145, a regulator of vascular smooth muscle cells, which focuses on application in hypertension and other vascular diseases to reduce pathological vascular remodeling and lower blo...
6200 Lookout Road
Boulder, CO 80301
Founded in 2006
Key Executives for miRagen Therapeutics, Inc.
Co-Founder, Chief Executive Officer, President and Director
Co-Founder and Chairman of The Board
Co-Founder and Member of Scientific Advisory Board
Co-Founder and Member of the Scientific Advisory Board
Compensation as of Fiscal Year 2014.
miRagen Therapeutics, Inc. Key Developments
Servier and miRagen Extend Collaboration for the Research, Development and Commercialization of microRNA-targeting Drugs for Cardiovascular Disease
Jun 23 14
Servier, and miRagen Therapeutics, Inc. announced that they have extended their research collaboration by two years to October 2016 to discover, develop, and commercialize drugs targeting microRNAs for cardiovascular disease. miRagen and Servier Research will continue preclinical research and development on multiple cardiovascular programs targeting microRNAs, including miR-208 and miR-15. Servier will lead the global clinical development and commercialization of microRNA therapeutic product candidates developed through the collaboration in all countries except the U.S. and Japan, where miRagen has retained all rights.
miRagen Therapeutics, Inc. Appoints David Rodman as Executive Vice President of Research and Development
Mar 25 14
miRagen Therapeutics, Inc. announced the appointment of David Rodman, M.D. to the position of Executive Vice President of Research and Development. Dr. Rodman is an accomplished industry veteran who brings significant translational medicine and clinical development experience to the company's executive leadership team. Prior to joining miRagen, Dr. Rodman was a Vice President of Clinical Development at Vertex Pharmaceuticals Incorporated, and before that he was Executive Director, Respiratory Translational Medicine at the Novartis Institutes for Biomedical Research.
miRagen Therapeutics, Inc. Announces Executive Appointments
Jun 11 13
miRagen Therapeutics, Inc. announced the appointments of Christopher J. Morl, M.B.A., B.Sc. (Hons), as Chief Business Officer and Aimee L. Jackson, Ph.D., as Director of Target Development. Mr. Morl and Dr. Jackson are biotech and pharmaceutical industry veterans and bring significant strategic and technical experience to the company's senior leadership team. Prior to joining miRagen, Mr. Morl worked as a consultant advising pre-clinical and clinical stage biotech companies on corporate strategy, business development and financing. He serves as a Director of the Board of Alethia Biotherapeutics Inc., where he is also Chairman of the Audit Committee. After receiving her Ph.D. from the University of Colorado Health Science Center and completing her post-doctoral training, Dr. Jackson joined Rosetta Inpharmatics/Merck in Seattle, where her team established the use of expression profiling technologies combined with RNAi for target identification, target validation, elucidation of drug mechanism-of-action, and patient stratification.
Similar Private Companies By Industry
Recent Private Companies Transactions
February 3, 2015